Skip to main content
. 2019 Sep 11;9(9):474. doi: 10.3390/biom9090474

Figure 1.

Figure 1

Connexin43 (Cx43) expression in control, oculodentodigital dysplasia (ODDD) patient-derived, and CRISPR-Cas9 knockout human iPSCs. (A) Human induced pluripotent stem cells (iPSCs) reprogrammed from control or ODDD patient-derived dermal fibroblasts, as well as CRISPR-Cas9-engineered Cx43-/- iPSCs, were immunofluorescently labeled for connexin43 (Cx43, green). Scale bar = 100 μm. (B) Confocal microscopy of Cx43 (green) in control and ODDD patient-derived iPSCs revealed the typical punctate distribution of Cx43 at cell-cell interfaces. Scale bar = 20 μm. (C) Representative immunoblots of Cx43 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in two control, and two Cx43-/- iPSCs cell populations generated through CRISPR-Cas9 engineering.